SEATTLE, Jan. 4, 2018 /PRNewswire/ — LumiThera a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Digital Medicine and MedTech ShowcaseTM 2018, to be held January 8-10 during the most important week in healthcare at the Parc 55… Continue reading
SEATTLE, November 7, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced topline interim results from the LIGHTSITE I trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded from… Continue reading
SEATTLE, October 31, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed the Series B round of financing. The company raised $5.5M to support further development of its LT-300 device for the treatment for dry Age-related… Continue reading
SEATTLE, April 18, 2017 /PRNewswire/ — LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France. Biovision is a high-level investor event connecting… Continue reading
SEATTLE, May 5, 2016 /PRNewswire/ — LumiThera® Inc., a late stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease today announced that Graham Merry, MBBS presented clinical data results from the TORPA II study in Dry Age-Related Macular Degeneration (AMD) subjects at the Association for Research in Vision… Continue reading
SEATTLE, April 27, 2016 /PRNewswire/ — LumiThera ® Inc., a late-stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has been awarded the prestigious “MOST PROMISING AND INNOVATIVE CATALYZER AWARD” during Biovision 2016, Lyon, France. Biovision is a high-level investor event connecting industrial partners, financial… Continue reading
SEATTLE, March 24, 2016 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has obtained Health Canada approval of their LIGHTSITE clinical study to treat dry Age-related Macular Degeneration (AMD) subjects. The pilot clinical trial is in part sponsored by… Continue reading
SEATTLE, Sept. 29, 2015 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a two small business innovative research (SBIR) phase I grants from the National Institute of Health (NIH) and the division of the National… Continue reading
SEATTLE, May 27, 2015 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, announced today that they were awarded a Washington State Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was 1 of 3 recipients of the LSDF matching grants worth $500,000 to… Continue reading
SEATTLE, May 6, 2015 /PRNewswire/ — LumiThera Inc., a medical device company focused on the development of non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced Retired Congressman Norman Dicks has agreed to join LumiThera’s Advisory Board to assist in the company’s mission to treat vision impairment. Norman DeValois “Norm” Dicks was the… Continue reading
